Trial ID or NCT#

NCT01482767

Status

not recruiting iconNOT RECRUITING

Purpose

Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.

Official Title

A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Andrew Zolopa
Philip Grant
Philip Grant
Positive care doctor, Infectious disease doctor
Assistant Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Debbie Slamowitz, RN
(650) 723-2804